zeltia sa (ZLIXF) Key Developments
Zeltia Reports Earnings Results for the First Quarter of 2015
Apr 29 15
Zeltia reported earnings results for the first quarter of 2015. For the period, the company's net profit dropped 61% to EUR 6.5 million (USD 7.1 million) compared with EUR 16.9 million in the equivalent period of 2014. Net sales in the biopharmaceutical sector amounted to EUR 21.1 million, compared with EUR 20.9 million in first-quarter 2014. The main reason for Zeltia's negative financial performance during the beginning of the year is the reduction in milestone payment under an agreement signed with Janssen in 2011 on the development of oncology product Yondelis, which for first-quarter 2015 corresponded to only USD 10 million, compared with USD 25 million in first-quarter 2014.
Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015
Apr 21 15
Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: José-Luis Moreno, IR & Capital Markets Director.
Zeltia SA Reports Earnings Results for the Full Year 2014
Feb 26 15
Zeltia SA reported earnings results for the full year 2014. For the year, the company reported group total revenues amounted to EUR 178 million up 8% with respect to EUR 164.7 million in 2013. Group EBITDA amounted to EUR 25.7 million, up 8% year-on-year. This improvement in operating profit was achieved despite the increase in R&D spending, which amounted to EUR 52.5 million in 2014, up 23% year-on-year. Of that figure, EUR 45.3 million corresponds to the oncology area. net attributable profit amounted to EUR 13.1 million, compared with EUR 11.3 million in 2013 (+16%).
Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015
Dec 15 14
Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.
Zeltia Reports Earnings Results for the Nine Months Ended September 2014
Oct 30 14
Zeltia reported earnings results for the nine months ended September 2014. For the period, the company's net sales grew by 7% year on year to EUR 116.9 million. Net profit amounted to EUR 17.5 million, a 24.3% increase compared with the same period in 2013. Positive performance was driven mainly by star oncology product Yondelis (trabectedin), net sales of which reached EUR 57 million, and the net sales of Biofarmacia increased by 7% to EUR 61.2 million.